BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25284102)

  • 1. Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review.
    Slim E; Antoun J; Kourie HR; Schakkal A; Cherfan G
    Can J Ophthalmol; 2014 Oct; 49(5):450-7. PubMed ID: 25284102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors.
    Saito W; Kase S; Fujiya A; Dong Z; Noda K; Ishida S
    Retina; 2013 Oct; 33(9):1959-67. PubMed ID: 23652580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab and feeder vessel laser treatment for a posteriorly located retinal capillary hemangioma.
    Agarwal A; Kumari N; Singh R
    Int Ophthalmol; 2016 Oct; 36(5):747-50. PubMed ID: 26815929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma.
    Mennel S; Meyer CH; Callizo J
    Acta Ophthalmol; 2010 Aug; 88(5):610-3. PubMed ID: 19222401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The Use of anti-VEGF preparations and PDT in the treatment of retinal juxtapapillary hemangioma - a case report].
    Matušková V; Vysloužilová D
    Cesk Slov Oftalmol; 2014 Oct; 70(5):196-200. PubMed ID: 25640043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Results of Various Treatments for Retinal Capillary Hemangioma.
    Won YK; Lee MW; Shin YI; Kim JY; Jo YJ
    Korean J Ophthalmol; 2020 Apr; 34(2):133-142. PubMed ID: 32233147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
    Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
    Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
    Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
    Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma.
    Russo V; Stella A; Barone A; Scott IU; Noci ND
    Int Ophthalmol; 2012 Feb; 32(1):71-5. PubMed ID: 22271068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
    Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
    Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
    Kim M; Lee P; Kim Y; Yu SY; Kwak HW
    Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab in inflammatory ocular neovascularization.
    Mansour AM; Mackensen F; Arevalo JF; Ziemssen F; Mahendradas P; Mehio-Sibai A; Hrisomalos N; Lai TY; Dodwell D; Chan WM; Ness T; Banker AS; Pai SA; Berrocal MH; Tohme R; Heiligenhaus A; Bashshur ZF; Khairallah M; Salem KM; Hrisomalos FN; Wood MH; Heriot W; Adan A; Kumar A; Lim L; Hall A; Becker M
    Am J Ophthalmol; 2008 Sep; 146(3):410-416. PubMed ID: 18619571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.
    Jonas JB; Tao Y; Rensch F
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):401-5. PubMed ID: 21810019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical Exophytic Retinal Capillary Hemangioma and Diagnostic Modalities.
    Shechtman DL; Gold AS; McIntosh S; Steen J; Murray TG
    Optom Vis Sci; 2016 Jan; 93(1):107-12. PubMed ID: 26583797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.
    Jonas JB; Tao Y; Schlichtenbrede FC
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):467-70. PubMed ID: 21682590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma.
    Sachdeva R; Dadgostar H; Kaiser PK; Sears JE; Singh AD
    Acta Ophthalmol; 2010 Dec; 88(8):e334-40. PubMed ID: 20946329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.